

FOI – 1927

9th October 2023

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

**Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of June 2023 and end of August 2023?
Please provide data for the latest 3-month period, if Jun to Aug is not available yet**

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	9
1.2 Alpelisib (Piqray)	0
1.3 Fulvestrant (fulvestrant or Faslodex)	<i>Information not held by Pharmacy Department</i>
1.4 Palbociclib (Ibrance)	23
1.5 Ribociclib (Kisqali)	10

**Q2. How many patients received abemaciclib (Verzenios) for early breast cancer in the 3 months between the start of June 2023 and end of August 2023?
Please provide data for the latest 3-month period, if Jun to Aug is not available yet**

Number patients treated
<i>See below</i>

Q3. How many patients received abemaciclib (Verzenios) as adjuvant treatment for early breast cancer in the

3 months between the start of June 2023 and end of August 2023?

Please provide data for the latest 3-month period, if Jun to Aug is not available yet

Number patients treated
7

Q4. How many patients received abemaciclib (Verzenios) with the following treatment intent in the 3 months between the start of June 2023 and end of August 2023?

Please provide data for the latest 3-month period, if Jun to Aug is not available yet

Treatment intent	Number patients treated
4.1 Curative	7
4.2 Palliative	2
4.3 Not known / stated	NA

Q5. How many patients were treated with the following medicines in combination in the 3 months between the start of June 2023 and end of August 2023?

Please provide data for the latest 3-month period, if Jun to Aug is not available yet

Name of combination or monotherapy	Number patients treated
5.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	1
5.2 Abemaciclib (Verzenios) + an aromatase inhibitor (anastrozole, letrozole or exemestane)	3
5.3 Abemaciclib (Verzenois) + tamoxifen	5
5.4 Abemaciclib monotherapy	0
5.5 Alpelisib (Piqray) + Fulvestrant (fulvestrant or Faslodex)	0
5.6 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	1
5.7 Palbociclib (Ibrance) + an aromatase inhibitor (anastrozole, letrozole or exemestane)	22
5.8 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	4
5.9 Ribociclib (Kisqali) + an aromatase inhibitor (anastrozole, letrozole or exemestane)	6

Note:

Question 2 requesting no of patients treated with Abemaciclib for early breast cancer. As per SPC:-

Early Breast Cancer

Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence (see section 5.1).

In pre- or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.

Therefore question 2 and 3 refer to the same patients.

Email: foi.team@southerntrust.hscni.net